← back to search

Chris Bailey

The Francis Crick Institute ·
Area of research
Cancer Research · Hardware and Architecture
Research interest
Research interests include Cancer Genomics and Diagnostics, Parallel Computing and Optimization Techniques, Human Pose and Action Recognition, and Glioma Diagnosis and Treatment.
h-index
32
citations
5,287
works
141
NIH funding
primary concept
Medicine
email

Recent publications

Ultrasensitive ctDNA detection for preoperative disease stratification in early-stage lung adenocarcinoma
Nature Medicine 2025cited by 75position: middledoi
Extrachromosomal DNA–Driven Oncogene Spatial Heterogeneity and Evolution in Glioblastoma
Cancer Discovery 2025cited by 11position: middledoi
Origins and impact of extrachromosomal DNA
Nature 2024cited by 134position: firstdoi
Combined analyses of within-host SARS-CoV-2 viral kinetics and information on past exposures to the virus in a human cohort identifies intrinsic differences of Omicron and Delta variants
PLoS Biology 2024cited by 19position: middledoi
COVID-19 in non-hospitalised adults caused by either SARS-CoV-2 sub-variants Omicron BA.1, BA.2, BA.4/5 or Delta associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history
PLoS ONE 2024cited by 11position: middledoi
In Situ Tracking of TCRβ Isoforms for Detection of T Cell Clonality: Implication for Precision Diagnosis and Targeted Immunotherapy of T‐Cell Neoplasms
Hematological Oncology 2024cited by 1position: middledoi
Lung adenocarcinoma promotion by air pollutants
Nature 2023cited by 728position: middledoi
The evolution of lung cancer and impact of subclonal selection in TRACERx
Nature 2023cited by 300position: middledoi
RETRACTED ARTICLE: Antibodies against endogenous retroviruses promote lung cancer immunotherapy
Nature 2023cited by 247position: middledoi
The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance
Nature Genetics 2023cited by 85position: middledoi
34 COVID-19 caused by either Omicron sub-variants or Delta in non-hospitalised adults associates with similar illness duration, symptom severity and viral kinetics, irrespective of vaccination history
Clinical Infection in Practice 2023cited by 2position: middledoi
Targeted profiling of human extrachromosomal DNA by CRISPR-CATCH
Nature Genetics 2022cited by 120position: middledoi
Extrachromosomal DNA—relieving heredity constraints, accelerating tumour evolution
Annals of Oncology 2020cited by 110position: firstdoi
Adult leukemia survival trends in the United States by subtype: A population‐based registry study of 370,994 patients diagnosed during 1995‐2009
Cancer 2018cited by 43position: firstdoi

Grants

No grants ingested yet.

Frequent collaborators

Miguel Á. Piris · Hospital Universitario Fundación Jiménez Díaz1 papers (2024–2024)Rhea Harewood · Imperial College London1 papers (2018–2018)Mathieu Ferrari · William Harvey Research Institute1 papers (2024–2024) · 1 papers (2018–2018)Alan G. Ramsay · King's College London1 papers (2024–2024)Claudia Allemani · University College London1 papers (2018–2018) · 1 papers (2024–2024) · 1 papers (2018–2018) · 1 papers (2024–2024) · 1 papers (2024–2024)Teresa Marafioti · University College London Hospitals NHS Foundation Trust1 papers (2024–2024)Audrey Bonaventure · London School of Hygiene & Tropical Medicine1 papers (2018–2018)Massa J. Shoura · Luminomics (United States)1 papers (2020–2020)David C. Linch · CRUK Lung Cancer Centre of Excellence1 papers (2024–2024)Brunangelo Falini · University of Perugia1 papers (2024–2024) · 1 papers (2024–2024)Charles Swanton · Cancer Evolution and Genome Instability Laboratory1 papers (2020–2020)Kate Cwynarski · University College Hospital1 papers (2024–2024)Martin Pulé · London Cancer1 papers (2024–2024) · 1 papers (2024–2024)